Malonic Acid 3-Tert-Butoxycarbonylamino-Propyl Ester Ethyl Ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Malonic Acid 3-Tert-Butoxycarbonylamino-Propyl Ester Ethyl Ester
• 英文别名: 1-O-ethyl 3-O-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl] propanedioate
• 化学式: C₁₃H₂₃NO₆
• 分子量: 289.329
• InChiKey: RZTLUTGCKKAXSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  90.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Malonic Acid 3-Tert-Butoxycarbonylamino-Propyl Ester Ethyl Ester 、 足球烯 在 碘 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲苯 为溶剂， 反应 0.5h， 以54%的产率得到
  参考文献：
  名称：

  A Fullerene−Paclitaxel Chemotherapeutic:  Synthesis, Characterization, and Study of Biological Activity in Tissue Culture

  摘要：

  A fullerene-paclitaxel conjugate has been synthesized as a slow-release drug for aerosol liposome delivery of paclitaxel for lung cancer therapy. The conjugate was designed to release paclitaxel via enzymatic hydrolysis and subsequently has shown a half-life of release of 80 min in bovine plasma. A liposome formulation of the conjugate has been prepared using dilauroylphosphatidylcholine (DLPC), and its IC50 is virtually identical to the IC50 for a paclitaxel-DLPC formulation in human epithelial lung carcinoma A549 cells. With both clinically relevant kinetics of hydrolysis and significant cytotoxicity in tissue culture, the conjugate holds promise for enhanced therapeutic efficacy of paclitaxel in vivo.

  DOI：

  10.1021/ja0546525
• 作为产物：
  描述：

  N-(3-羟丙基)氨基甲酸叔丁酯 、 氯甲酰乙酸乙酯 生成 Malonic Acid 3-Tert-Butoxycarbonylamino-Propyl Ester Ethyl Ester
  参考文献：
  名称：

  Nanostructure-Drug Conjugates

  摘要：

  提供了纳米结构药物共轭物及其使用方法。在一个实施例中，提供了一种纳米结构药物共轭物，包括Cn，交联剂和药物，其中Cn指的是含有n个碳原子的富勒烯基团或纳米管。还提供了一种治疗癌症的方法，包括向哺乳动物注射治疗有效量的纳米结构药物共轭物，其中包括Cn，交联剂和药物，其中Cn指的是含有n个碳原子的富勒烯基团。

  公开号：

  US20080175892A1

文献信息

• Targeted Nanostructures for Cellular Imaging
  申请人：Wilson Lon J.

  公开号：US20090214101A1

  公开（公告）日：2009-08-27

  Compositions and methods related to targeted carbon nanostructures. More particularly, targeted carbon nanostructures comprising: a C n , a cross-linker, and a targeting agent, wherein C n refers to a fullerene moiety or nanotube comprising n carbon atoms. One example of a method may involve a method for imaging comprising: contacting a targeted carbon nanostructure and a cell; allowing the cell to internalize the carbon nanostructure; and detecting the presence of internalized carbon nanostructures.

  与靶向碳纳米结构相关的组合物和方法。更具体地，所述靶向碳纳米结构包括：一个Cn，一个交联剂和一个靶向试剂，其中Cn指的是包含n个碳原子的富勒烯基团或纳米管。一个方法的一个示例可能涉及一种成像方法，包括：接触靶向碳纳米结构和一个细胞；使细胞内化碳纳米结构；并检测内化的碳纳米结构的存在。
• Nanostructure-Drug Conjugates
  申请人：Wilson Lon J.

  公开号：US20080175892A1

  公开（公告）日：2008-07-24

  Nanostructure-drug conjugates and associated methods of use are provided. In one embodiment, a nanostructure-drug conjugate comprising a C n , a crosslinker, and a drug is provided, wherein C n refers to a fullerene moiety or nanotube comprising n carbon atoms. A method of treating cancer is also provided, comprising administering a therapeutically effective amount of a nanostructure-drug conjugate comprising: a C n , a crosslinker, and a drug, wherein C n refers to a fullerene moiety comprising n carbon atoms to a mammal.

  提供了纳米结构药物共轭物及其使用方法。在一个实施例中，提供了一种纳米结构药物共轭物，包括Cn，交联剂和药物，其中Cn指的是含有n个碳原子的富勒烯基团或纳米管。还提供了一种治疗癌症的方法，包括向哺乳动物注射治疗有效量的纳米结构药物共轭物，其中包括Cn，交联剂和药物，其中Cn指的是含有n个碳原子的富勒烯基团。
• [EN] TARGETED NANOSTRUCTURES FOR CELLULAR IMAGING<br/>[FR] NANOSTRUCTURES CIBLÉES UTILES POUR UNE IMAGERIE CELLULAIRE
  申请人：UNIV RICE WILLIAM M

  公开号：WO2007143558A1

  公开（公告）日：2007-12-13

  [EN] Compositions and methods related to targeted carbon nanostructures. More particularly, targeted carbon nanostructures comprising: a C_n, a cross-linker, and a targeting agent, wherein Cn refers to a fiillerene moiety or nanotube comprising n carbon atoms. One example of a method may involve a method for imaging comprising: contacting a targeted carbon nanostructure and a cell; allowing the cell to internalize the carbon nanostructure; and detecting the presence of internalized carbon nanostructures.
  [FR] La présente invention concerne des compositions et des procédés associés à des nanostructures de carbone ciblées. Plus particulièrement, les nanostructures de carbone ciblées contiennent : un groupement C_n, un agent de réticulation et un agent de ciblage, C_n représentant un groupement fullerène sous forme d'un nanotube comportant n atomes de carbone. Un exemple de procédé peut inclure un procédé d'imagerie consistant à : mettre en contact une nanostructure de carbone ciblée et une cellule, permettre à la cellule d'absorber la nanostructure de carbone, et détecter la présence de nanostructures de carbone absorbées.
• A Fullerene−Paclitaxel Chemotherapeutic:  Synthesis, Characterization, and Study of Biological Activity in Tissue Culture
  作者：Tatiana Y. Zakharian、Alexander Seryshev、Balaji Sitharaman、Brian E. Gilbert、Vernon Knight、Lon J. Wilson

  DOI：10.1021/ja0546525

  日期：2005.9.1

  A fullerene-paclitaxel conjugate has been synthesized as a slow-release drug for aerosol liposome delivery of paclitaxel for lung cancer therapy. The conjugate was designed to release paclitaxel via enzymatic hydrolysis and subsequently has shown a half-life of release of 80 min in bovine plasma. A liposome formulation of the conjugate has been prepared using dilauroylphosphatidylcholine (DLPC), and its IC50 is virtually identical to the IC50 for a paclitaxel-DLPC formulation in human epithelial lung carcinoma A549 cells. With both clinically relevant kinetics of hydrolysis and significant cytotoxicity in tissue culture, the conjugate holds promise for enhanced therapeutic efficacy of paclitaxel in vivo.